ELAN logo

Elanco Animal Health Incorporated Stock Price

NYSE:ELAN Community·US$11.7b Market Cap
  • 4 Narratives written by author
  • 0 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author

ELAN Share Price Performance

US$22.68
12.37 (119.98%)
US$30.00
Fair Value
US$22.68
12.37 (119.98%)
24.4% undervalued intrinsic discount
US$30.00
Fair Value
Price US$22.68
Vestra US$30.00
AnalystConsensusTarget US$25.92
AnalystLowTarget US$22.49

ELAN Community Narratives

Vestra·
Fair Value US$30 24.4% undervalued intrinsic discount

Elanco Animal Health (ELAN): Unleashing the "Big Six" – From Pipeline Innovation to Market Leadership.

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystConsensusTarget·
Fair Value US$25.92 12.5% undervalued intrinsic discount

Upcoming Launches And Market Developments Will Shape Earnings Expectations This Year

0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AnalystLowTarget·
Fair Value US$22.49 0.9% overvalued intrinsic discount

Mounting Debt And Patent Risks Will Crush Future Net Margins

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$25.92
12.5% undervalued intrinsic discount
Revenue
5.28% p.a.
Profit Margin
3.17%
Future PE
94.09x
Price in 2029
US$32.09
US$29.84
24.0% undervalued intrinsic discount
Revenue
7.66% p.a.
Profit Margin
18.59%
Future PE
17.25x
Price in 2029
US$36.91

Trending Discussion

Updated Narratives

ELAN logo

Elanco Animal Health (ELAN): Unleashing the "Big Six" – From Pipeline Innovation to Market Leadership.

Fair Value: US$30 24.4% undervalued intrinsic discount
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
ELAN logo

ELAN: Dermatology And Pet Health Pipeline Optimism Will Test Execution And Margins

Fair Value: US$22.49 0.9% overvalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
ELAN logo

ELAN: New Pet Health Launches And Balance Sheet Progress Will Shape Outlook

Fair Value: US$25.92 12.5% undervalued intrinsic discount
10 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Very undervalued with adequate balance sheet.

0 Risks
4 Rewards

Elanco Animal Health Incorporated Key Details

US$4.7b

Revenue

US$2.1b

Cost of Revenue

US$2.6b

Gross Profit

US$2.8b

Other Expenses

-US$232.0m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.47
54.99%
-4.92%
62.1%
View Full Analysis

About ELAN

Founded
1954
Employees
9650
CEO
Jeffrey Simmons
WebsiteView website
www.elanco.com

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.

Recent ELAN News & Updates

Recent updates

No updates